ACM
FLGT icon

Aster Capital Management’s Fulgent Genetics FLGT Stock Holding History

Aster Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46
Closed -$1.21K – 1018
2025
Q4 		$1.21K Buy
+46
New +$1.19K ﹤0.01% 997

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aster Capital Management's FLGT Position: Q1 2026 in Review

Aster Capital Management sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 46 shares — an estimated $1.21K sold.

Aster Capital Management first reported a position in FLGT in Q4 2025 and held it in 1 quarter. The position peaked at $1.21K in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Aster Capital Management reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 46 Fulgent Genetics shares in Q1 2026, an estimated $1.21K.
  • Aster Capital Management first reported a position in Fulgent Genetics in Q4 2025 and held it in 1 quarter.
  • Aster Capital Management's Fulgent Genetics position peaked at $1.21K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.